Futuximab
- Generic Name
- Futuximab
- Drug Type
- Biotech
- CAS Number
- 1310460-85-5
- Unique Ingredient Identifier
- B37J680LX0
- Background
Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
Sym004 Versus TAS-102 in Patients With mCRC
- Conditions
- Metastatic Colorectal CancerColorectal Cancer MetastaticCarcinoma
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Symphogen A/S
- Registration Number
- NCT03717038
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
- Conditions
- Colorectal Cancer MetastaticMetastatic Colorectal CancerCarcinoma
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 2
- Registration Number
- NCT03549338
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇪🇸Hospital Clínico de Valencia, Valencia, Spain
🇩🇪Asklepios Kliniken Altona, Hamburg, Germany
Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Symphogen A/S
- Registration Number
- NCT02965417
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Symphogen A/S
- Registration Number
- NCT02924233
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 10
- Registration Number
- NCT02568046
- Locations
- 🇺🇸
Sharp Memorial Hosptal, San Diego, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Japanese Phase 1 Trial of Sym004 in Solid Tumors
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 51
- Registration Number
- NCT01955473
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01417936
- Locations
- 🇫🇷
3303; Centre Alexis Vautrin; Département d'Oncologie Médicale, Nancy, Vandoeuvre Les Nancy, France
🇩🇪4901; Universitätsklinikum Essen, Essen, Germany
🇩🇪4904; Universitätsklinikum Freiburg, Freiburg, Germany
Sym004 in Patients With Advanced Solid Tumors
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 111
- Registration Number
- NCT01117428
- Locations
- 🇪🇸
Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇧🇪UZ Antwerp, Oncologie, Edegem, Belgium
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.